Form 4: Provectus Biopharmaceuticals President Acquires Convertible Preferred Stock

Dominic Rodrigues, President of Provectus Biopharmaceuticals, reports acquisition of Series D-1 Convertible Preferred Stock convertible into 1,962,500 shares of common stock.

Summary

• On September 30, 2024, Dominic Rodrigues, President of Provectus Biopharmaceuticals, acquired 196,250 shares of Series D-1 Convertible Preferred Stock.
• Each share of Series D-1 Convertible Preferred Stock is convertible into 10 shares of the company's common stock.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted.
• Following the transaction, Rodrigues beneficially owns 1,337,876 shares of common stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral as it is a standard disclosure of an insider transaction. The acquisition of preferred stock could be seen as a positive sign, but without further context, it's difficult to assess the overall impact.

Positives

• The acquisition of convertible preferred stock by the President could signal confidence in the company's future prospects.

Future Outlook

The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless earlier converted into Common Stock in accordance with the terms of the Certificate of Designation for the Series D-1 Convertible Preferred Stock.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• Shareholders may view the insider's purchase of convertible preferred stock as a positive signal.

Key Dates